In the BioHarmony Drug Report Database

"Preview" Icon

Gatifloxacin

Zymar, Zymaxid (gatifloxacin) is a small molecule pharmaceutical. Gatifloxacin was first approved as Zymar on 2003-03-28. It is used to treat bacterial conjunctivitis, bacterial infections, bacterial pneumonia, bronchitis, and cystitis amongst others in the USA.

 

Trade Name

 

Zymar, Zymaxid
 

Common Name

 

gatifloxacin
 

ChEMBL ID

 

CHEMBL31
 

Indication

 

bacterial conjunctivitis, bacterial infections, bacterial pneumonia, bronchitis, cystitis, escherichia coli infections, gonorrhea, haemophilus infections, klebsiella infections, proteus infections, protozoan infections, pyelonephritis, salmonella infections, sinusitis, staphylococcal infections, streptococcal infections, urinary tract infections
 

Drug Class

 

Antibacterials (quinolone derivatives)

Image (chem structure or protein)

Gatifloxacin structure rendering